Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
Joint Authors
Rudiger, Alain
Arrigo, Mattia
Salzberg, Sacha P.
Bettex, Dominique
Breitenstein, Alexander
Source
Critical Care Research and Practice
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-05-12
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Objectives.
This study investigates the suitability, safety, and efficacy of vernakalant in critically ill patients with new onset atrial fibrillation (AF) after cardiac surgery.
Methods.
Patients were screened for inclusion and exclusion criteria according to the manufacturers’ recommendations.
Included patients were treated with 3 mg/kg of vernakalant over 10 min and, if unsuccessful, a second dose of 2 mg/kg.
Blood pressure was measured continuously for 2 hours after treatment.
Results.
Of the 191 patients screened, 159 (83%) were excluded, most importantly due to hemodynamic instability (59%).
Vernakalant was administered to 32 (17% of the screened) patients.
Within 6 hours, 17 (53%) patients converted to sinus rhythm.
Blood pressure did not decrease significantly 10, 30, 60, and 120 minutes after the vernakalant infusion.
However, 11 patients (34%) experienced a transient decrease in mean arterial blood pressure <60 mmHg.
Other adverse events included nausea (n=1) and bradycardia (n=2).
Conclusions.
Applying the strict inclusion and exclusion criteria provided by the manufacturer, only a minority of postoperative ICU patients with new onset AF qualified for vernakalant.
Half of the treated patients converted to sinus rhythm.
The drug was well tolerated, but close heart rate and blood pressure monitoring remains recommended.
American Psychological Association (APA)
Rudiger, Alain& Breitenstein, Alexander& Arrigo, Mattia& Salzberg, Sacha P.& Bettex, Dominique. 2014. Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-501209
Modern Language Association (MLA)
Rudiger, Alain…[et al.]. Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice No. 2014 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-501209
American Medical Association (AMA)
Rudiger, Alain& Breitenstein, Alexander& Arrigo, Mattia& Salzberg, Sacha P.& Bettex, Dominique. Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-501209
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-501209